



imeXHS

Investor Presentation

Capital Raising

3 August 2022

Disclaimer

Disclaimer

This presentation has been prepared by, and is the sole responsibility of, IMEXHS Limited ACN 096 687 839 (**the Company**) and is dated 3 August 2022. The Company is under no obligation to update or keep the information represented in this presentation current past the date of presenting. All information is subject to change without notice.

This presentation contains summary information about the Company as at the date of this presentation (unless otherwise stated) and has been prepared in relation to a placement of fully paid ordinary shares in the Company (**Shares**) (**Institutional Placement**) and a pro-rata non-renounceable entitlement offer of Shares (**Entitlement Offer**).

Confidentiality

This document and the information in this document (**Confidential Information**) is strictly confidential. You must not copy, reproduce, quote or refer to the Confidential Information or give it to another person, in whole or in part, without the prior written consent of the Company, which may be withheld in its absolute discretion.

Limitation of financial product advice

At no time should this presentation be considered to be the giving of financial product advice by the Company, its directors, officers, employees, agents or advisors. The information contained in the presentation has been prepared without regard to the recipients' financial circumstances or investment objectives. It is incumbent upon the recipient to make its own independent assessment of the Company and take independent advice as necessary.

Use of third party information

Any information or views expressed in this presentation were prepared by the Company. Information contained may have been obtained from publicly available sources that have not been independently verified. No warranty or representation is made to the accuracy of any third-party information contained in this presentation, and no responsibility or liability is accepted by the Company, its directors, officers, employees, agents or advisors for errors, omissions or misstatements made.

Forward-looking statements

Any forward-looking statements contained in this presentation are made by the Company based on information available at the time of the presentation. Although the Company believes these statements to be made based on reasonable assumptions, they are not guarantees of future performance. There are known and unknown risk factors beyond the control of the Company that may affect the Company's performance in relation to these forward-looking statements. Actual results may differ materially to that of the statements contained in this presentation.

Disclaimer

No offer of securities

Information contained in this presentation does not constitute an offer to sell or a solicitation of an offer to buy or sell Company securities in any jurisdiction. This presentation is not a prospectus, product disclosure document, or other offering document or contract under Australian law or any other law.

Effect of Rounding

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Currency

All financial information in this presentation is in Australian Dollars (\$) or AUD) unless otherwise stated. Certain amounts have been converted into Australian Dollars for the purpose of this presentation. In particular, a significant portion of the Company's revenues and expenses are denominated in Colombian Pesos.

Financial data

Investors should be aware that certain financial measures included in this presentation are 'non-IFRS financial information' under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and are not recognised under International Financial Reporting Standards (IFRS). The principal non-IFRS financial measures that are referred to in this presentation are EBITDA, Underlying EBITDA and Annualised Recurring Revenue. EBITDA is earnings before interest, tax, depreciation and amortisation and significant items. Management uses EBITDA to evaluate the operating performance of the business prior to the impact of significant items, the non-cash impact of depreciation and amortisation and interest and tax charges. Underlying EBITDA further excludes the foreign exchange, share based payments and other one-off costs. ARR is contracted annual recurring revenue (both billing and yet to commence billing). Management uses ARR to assess and monitor growth of the business.

The Company believes the non-IFRS financial information provides useful information to users in measuring the financial performance and conditions of the Company. The non-IFRS financial information do not have a standardised meaning prescribed by IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other entities. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial information included in this presentation.

Disclaimer

Neither the Company, Morgans Corporate Limited (**the Lead Manager**) or any of their respective related bodies corporate and affiliates, and their respective officers, directors, employees, agents, partners, contractors or advisers (collectively, Associated Persons) represents or warrants in any way, express or implied, that the information, opinions, conclusions or other information contained in this presentation, is fair, accurate, complete, up to date or correct.

Disclaimer

To the maximum extent permitted by law, the Company, the Lead Manager and their respective Associated Persons each expressly disclaims and excludes all liability that may arise from this presentation, or the use of or reliance on anything contained in or omitted from this presentation, or any other written or oral information provided by or on behalf of the Company.

Foreign selling restrictions

The distribution of this document in jurisdictions outside Australia may be restricted by law. In particular, this presentation may not be distributed to any person, and securities may not be offered or sold in any country outstanding Australia except to the extent permitted in the Foreign Selling Restrictions (see page 34 of this presentation). Persons who come into possession of this presentation who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

In particular, this presentation and the information contained in it does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. This presentation may not be distributed or released in the United States. The Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**the U.S. Securities Act**) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Shares may not be offered or sold, directly or indirectly, in the United States absent registration or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws.

Acceptance


By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to be bound by the terms and conditions set out in this disclaimer.

Agenda



Q2 FY2022 Results and Capital Raising

- 1. IMEXHS Overview**
- 2. 1H FY22 Results**
- 3. Business Update**
- 4. Outlook**
- 5. Capital Raising**



imexHS

Overview

Investment Highlights



Strong year-on-year growth across all key metrics

Contracted Annualised Recurring Revenue of \$20.5m, up 61% year on year

Strong pipeline of opportunities incl. two material near-term opportunities


Founder led and quality board and management
co-aligned with c28% shareholding

Business to reach underlying EBITDA positive and monthly cashflow run rate breakeven by CY22
Path to Profit

Disruptive, proprietary, cloud based software model is highly scalable with large global TAM.

One Company with two businesses aimed at democratising access to medical expertise

imexHS



Medical Imaging Software

Provider of innovative, cloud-based, AI medical imaging software solutions

Radiology Services

Outsourcing of imaging facilities and teleradiology to hospitals and medical facilities

Our 10-year Journey

The logo for imexHS, with 'imex' in blue and 'HS' in green, set against a background of a network diagram with green nodes and lines.

- | 2012 | • **Founded in Bogota, Colombia to provide access to medical technology in hard-to-reach areas**
- | 2015 | • **Expanded into countries in Latin America such as Ecuador and Mexico**
- | 2018 | • **Listed on the Australian Securities Exchange to expand our global presence**
- | 2019 | • **Received FDA Clearance in the US, expanded into new medical verticals & AI tools**
- | 2020 | • **Launched a standardized radiology imaging solution, AQUILA Cloud, and expanded into the US**
- | 2021 | • **Purchased RIMAB SAS to strengthen radiology services business to access vast amounts of data for AI development**

Expanding global footprint



Software

15 countries; 418 sites
2,650+ radiologists
35 distributors in 15 countries
37 engineers

Services

Colombia, Spain and Mexico
33 radiology centres
130+ in-house radiologists



1H FY22 Results



1H FY22¹ Financial Highlights

imexHS

Sales Revenue

Up 83% yoy
Up 82% on a constant
currency basis

\$9.5m

Annual Recurring Revenue (ARR)²

Up 61% yoy
Up 60% on a constant
currency basis

\$20.5m

EBITDA

vs (\$2.1m) in FY21

(\$0.5m)

Recurring revenue

Up 91% yoy
Up 90% on a constant
currency basis

\$9.3m

Closing cash

Vs \$4.2m at 31
December 2021

\$0.9m

Underlying EBITDA³

vs (\$1.4m) in FY21

(\$0.4m)

1. Unaudited preliminary financial information – subject to adjustment on completion of audit review.
2. ARR excludes customer with a poor payment record that the company ceased to service on 1 July 2022.
3. Underlying EBITDA excludes the impact of FX, share based payments, transaction costs for the RIMAB acquisition and any one-off costs in relation to the cost-out program.
4. Constant currency basis assumes FY22 results are converted at the average foreign exchange rate for FY21 of COP2,823. This removes the impact of changes in currency rates and allows comparison of IMEXHS's underlying operating performance.

1H FY22 Revenue and ARR Split

\$M	Medical Software Imaging	Radiology Services	Total
Revenue ¹	2.8	6.7	9.5
ARR ²	8.5	12.0	20.5

Notes:

1. Unaudited preliminary financial information – subject to adjustment on completion of audit review
2. ARR excludes customer with a poor payment record that the company ceased to service on 1 July 2022.

The logo for imexHS, with 'imex' in blue and 'HS' in green, set against a background of a network diagram with green nodes and lines.

- Software revenue primarily related to sales of AQUILA Enterprise
- Radiology services includes RIMAB along with other services related to outsourcing radiology on-premise or remotely using IMEXHS software



Business Update



1H FY22 Operational Highlights

- **IMEXHS Cloud** (formerly AQUILA in the Cloud)
140 contracts signed to date with ARR of \$2.8m
- Signed 6 **new partners** from 4 different countries and signed 2 **new Master Distributors** - Crowd IT in Australia and 3verest in the UK.
- Entered **Thai market** with FDA registration, a distribution agreement with BJC and an IMEXHS Cloud order
- Awarded **new expanded 3-year contract** with major hospital group Colsubsidio, for the outsourcing of its entire radiology services network at increased prices and additional services. Expected ARR to increase ~20% to \$7.2m
- **Renewed contract** with Colombia's National Police Force, with price increase of 15% increasing ARR to \$1.3m



Path to Profitability

- Cost out program aimed at getting to cash positive at the company level with both divisions profitable
- Development is directed towards near term profitable outcomes
- Sales capability directed towards immediate pipeline
- Maintaining current high medical and customer service standards
- Strategic vision and direction on course to be realised.

imexHS

Outlook

FY22 Outlook

FY22 guidance

- **Revenue** between \$18.0m to \$20.5m (vs \$13.4m in FY21)
- **Underlying¹ EBITDA** positive for 2022 (vs loss of \$1.4m in FY21)
- **Monthly run-rate Underlying Cash** breakeven during 2H FY22



- Initiatives to reach profitability and cashflow breakeven and maintaining the integrity of our 5-year strategic framework
- Strong and growing pipeline including advanced negotiation on two material contracts expected to be concluded within Q3

1. Underlying EBITDA and Underlying Cash excludes the impact of FX, share based payments, transaction costs for the RIMAB acquisition, any one-off costs in relation to the cost-out program and costs of raising capital.

imexHS

Capital Raising

Details of the Offer

Offer Structure and Size	<ul style="list-style-type: none">• A fully underwritten capital raising of approximately \$4.0m, comprising:• A fully underwritten Placement of \$2.0m, consisting of two parts:<ul style="list-style-type: none">• Tranche 1 – an institutional placement to raise approximately \$1.0m (“Institutional Placement”); and• Tranche 2 – a placement of approximately \$1.0m to Directors subject to shareholder approval with an EGM to be held in September (“Conditional Placement”); and• A fully underwritten 1 for 8 non-renounceable Entitlement Offer (“Entitlement Offer”) to existing shareholders as of the Record Date to raise approximately \$2.0m• The Placement and Entitlement Offer are together referred to as the (“Offer”)
Offer Price	<ul style="list-style-type: none">• Offer Price of \$0.48 per share represents a:<ul style="list-style-type: none">• 22.6% discount to the last close of \$0.62 on 29 July 2022;• 20.6% discount to the Theoretical Ex-Rights Price (“TERP”) of \$0.60
Director Participation	<ul style="list-style-type: none">• Directors and their associated entities have committed to subscribe for an aggregate of \$1.5m by way of taking up entitlements and commitments to subscribe for New Shares under the Placement
Use of Funds	<ul style="list-style-type: none">• At least \$0.5 million of the proceeds of the Offer will be used to pay down existing high yield debt. The balance of the funds raised under the Offer will be used for working capital and general business purposes¹• The Company believes that the funds to be raised will be adequate to see the Company through to a cashflow positive run rate
Ranking	<ul style="list-style-type: none">• Shares issued under the Offer will rank pari passu with existing Shares on issue
Underwriting	<ul style="list-style-type: none">• Morgans Corporate Limited is the Sole Lead Manager and Underwriter to the Offer

¹ If the Conditional Placement is not approved by shareholders the repayment of debt and working capital will be scaled back appropriately.

Indicative Timetable

INDICATIVE OFFER TIMETABLE	
Event	2022
Trading halt	(pre-market open) Monday, 1 August
Trading halt lifted – Shares recommence trading on ASX	Wednesday, 3 August
Record Date for Entitlement Offer	7.00pm (AEST) Monday, 8 August
Settlement of first tranche Placement	Tuesday, 9 August
Allotment and commencement of trading of New Shares issued under the Placement	Wednesday, 10 August
Entitlement Offer opens and Retail Offer Booklet (including Entitlement and Acceptance Form) dispatched	Thursday, 11 August
Entitlement Offer closes	Thursday, 25 August
Announcement of results of Entitlement Offer	Monday, 29 August
Settlement of New Shares under the Entitlement Offer	Wednesday, 31 August
Allotment of New Shares issued under the Entitlement Offer	Thursday, 1 September
Trading of New Shares issued under the Entitlement Offer	Friday, 2 September
Approval of Conditional Placement at EGM	September
Settlement of Conditional Placement	September
Allotment, quotation and trading of New Shares issued under the Conditional Placement	September

Use of Proceeds & Capital Structure

Sources	\$m
Placement	2.0
Entitlement Offer	2.0
Total	4.0
Uses ¹	\$m
Working Capital and costs of equity raising	3.5
Repayment of debt	0.5
Total	4.0

Capital Structure	\$m
Current Market Capitalisation at 29 July 2022	20.5
Equity Raising	4.0
Pro forma cash ²	(4.9)
Pro forma debt ²	1.5
Total Enterprise Valuation	21.1

1. If the Conditional Placement is not approved by shareholders the repayment of debt and working capital will be scaled back appropriately.

2. 30 June 2022 (unaudited) adjusted for the impact of the capital raising / repayment of debt (as applicable).

Directors	Shareholding pre-capital raising ¹	% pre-capital raising ¹	Placement Shares ²	Entitlement Shares	Shareholding post-capital raising	% post capital raising ³
Mr Douglas Flynn	787,054	2.39%	589,119	98,381	1,474,554	3.6%
Dr German Arango	4,426,201 ⁴	13.54%	-	416,666 ⁵	4,842,867	11.8%
Mr Carlos Palacio	2,088,199	6.34%	426,476	261,024	2,775,699	6.7%
Mr Damian Banks	511,527	1.55%	623,560	63,940	1,199,027	2.9%
Dr Douglas Lingard	849,579	2.58%	581,303	106,197	1,537,079	3.7%
Total	8,662,560	26.40%	2,220,458	946,208	11,829,226	28.7%

Notes:

1. Relevant interest in shares prior to the capital raising.
2. Subject to shareholder approval at an EGM in September 2022.
3. Maximum relevant interest in shares immediately following completion of the Offer assuming the Directors take up their entitlements in full (other than in respect of German Arango, see note 5 below) and shareholder approval is obtained for their subscriptions under the Placement.
4. Includes a relevant interest in shares held by Digital Imaging S.A.S Pty Ltd, an entity controlled by German Arango and includes 1,275,698 shares escrowed until 5 October 2022.
5. Includes German Arango's direct entitlement in full and part of his indirect entitlement via the shares held by Digital Imaging Solutions S.A.S, an entity which he is deemed to have a relevant interest in under the Corporations Act 2001 (Cth). In aggregate, German Arango has committed to subscribe for \$200,000 worth of new shares under the Entitlement Offer, directly and indirectly via Digital Imaging Solutions S.A.S.

Key Risks

This section sets out some of the key risks associated with any investment in IMEXHS, which may affect the value of IMEXHS Shares. The risks set out below are not necessarily listed in order of importance and do not constitute an exhaustive list of all risks involved with an investment in IMEXHS. Before participating in the Placement or Entitlement Offer, you should be aware that an investment in IMEXHS should be considered speculative and has a number of risks, some of which are specific to IMEXHS, some of which relate to listed securities generally, and some of which are beyond the control of IMEXHS.

Risk	Description
Competition and new technologies	<i>IMEXHS is subject to competition from other operators in Latin America and Asia-Pacific as well as Europe and the United States of America. The healthcare technology industry is competitive and includes companies with significant financial, technical, human, research and development and marketing resources. New or existing competitors may increase their market share including by acquiring or developing technologies which give them a competitive advantage, lowering the prices of their products and services or increasing the scale or range of their products and services. As emerging technologies continue to develop in the healthcare industry, there may be certain product developments that supersede IMEXHS's current and future products and services.</i>
Acceptance of products and services	<i>IMEXHS's business model depends on the ability to sell and deploy its products and services. Acceptance of IMEXHS's products and services requires hospitals, clinics, radiologists and physicians to adjust their behaviour and adopt new methods in replacement of traditional methods. There is no guarantee that hospitals and practitioners will integrate IMEXHS's products and services or that other participants in the healthcare market will accept IMEXHS's products and services.</i>
Failure to renew contracts and win new business	<i>New contracts, including contracts entered into with an existing client where a previous contract has expired, particularly with public hospitals may be subject to a competitive process. There is a risk that IMEXHS may not win these contracts for reasons including lower pricing from competitors, increased competition, inability to differentiate its products, failure to maintain quality or efficiency, failure to react to new developments or negative perceptions adversely affecting IMEXHS's brand and reputation.</i>

Key Risks

Risk	Description
Implementation of cost saving strategy	<i>IMEXHS is currently undertaking a cost reduction program. There is a risk that, if this program is not implemented efficiently, it may not deliver the anticipated benefits. The cost reduction program may also delay certain projects in development and may inhibit growth in the short term.</i>
Reliance on major customers	<i>IMEXHS has some degree of reliance on major customers. Some of these customers are on relatively short term contracts. The loss of a major customer, including by a failure to renew a major customer contract for the reasons set out above, could have a material impact on IMEXHS's revenue and therefore its financial performance.</i>
Payment risk	<i>There can be no guarantee that a customer will be able to meet its contractual payment obligations for the duration of its contract. Should a customer enter financial distress or become insolvent, IMEXHS may not be paid for the services provided under a contract and may need to terminate a contract where there has been payment defaults. Payment defaults by a major client in particular may have a material impact on IMEXHS's revenue and therefore its financial performance.</i>
Faults with products or services	<i>IMEXHS's primary business is the provision of imaging software platforms and medical imaging services. There is a risk that there may be errors or defects in the software or services provided, some of which may only be identified after customers commence use. Faults in IMEXHS's software platforms or provision of its medical imaging services may cause among other things harm to IMEXHS's reputation or brand, delays in or loss of market acceptance of IMEXHS's products and services and costs to remedy the errors if discovered after they are deployed. Faults discovered earlier may result in delays in new product releases and lost sales.</i>
Future Funding	<p><i>The funds to be raised under the Placement and Entitlement Offer are considered sufficient to meet the current objectives of IMEXHS. However, additional funding will be required to fund future growth strategies. The Conditional Placement is subject to the approval of IMEXHS shareholders. If shareholders do not approve the Conditional Placement, the applicable New Shares will not be able to be issued to the directors and the Company will only receive proceeds of \$2.9 million under the Offer. In this event, the Company may require further funding at an earlier time.</i></p> <p><i>IMEXHS may look to raise additional funding via equity or debt financing in the future. Failure to obtain sufficient funding may result in delay to the implementation of the Company's growth strategy and/or slower development and release of new technology. There can be no guarantee that additional funding will be available when needed, on terms favourable to IMEXHS or that do not involve substantial shareholder dilution.</i></p>

Key Risks

Risk	Description
Strategy for growth	<p><i>The future success of IMEXHS will depend on its ability to develop innovative solutions that keep pace with technological change, evolving industry standards and innovation in the medical imaging industry. There can be no certainty that the Company will be successful in adapting existing or developing new technology or services in a timely or cost-effective manner or that the solutions will be successful in the marketplace. A failure to keep pace with changes in technology, innovation and developments in medical imaging markets could diminish the Company's ability to retain and attract customers and retain our competitive position, which could adversely impact its business and results of operations.</i></p>
Reliance on key management personnel	<p><i>IMEXHS's success depends on the continued performance, efforts, abilities and expertise of its key management personnel. There is no guarantee that IMEXHS will be able to retain its key management personnel, or attract and retain suitability qualified personnel.</i></p>
Protection of intellectual property	<p><i>IMEXHS's trademarks, trade names, copyrights, trade secrets and other intellectual property rights are important to its success and unauthorised use of any of IMEXHS's intellectual property rights may adversely affect the financial performance and/or reputation of the business. There can be no assurances that IMEXHS will be able to prevent the unauthorised use of its intellectual property.</i></p>
Infringement of third party intellectual property rights	<p><i>If a third party accuses IMEXHS of infringing its intellectual property rights or if litigation is commenced against IMEXHS for the alleged infringement of patent or other intellectual property rights of a third party, IMEXHS may incur significant costs in defending such action and diversion of management's personnel's time, whether or not the alleged infringement occurred.</i></p>

Key Risks

Risk	Description
External technology risk	<i>IMEXHS uses off-the-shelf software (in addition to its own proprietary software) to enable the functionality of its product offerings. This external software may be subject to issues outside of IMEXHS's control such as third party interfaces, version conflict, obsolescence or other related issues. These external issues may affect the ability of IMEXHS to effectively upgrade and maintain its software. Any licensing or commercial conditions imposed by third party software providers may be unsustainable or impracticable for IMEXHS, which may result in a need for IMEXHS to obtain alternative solutions or develop these in house. There is no guarantee that IMEXHS would be able to do so or do so in a undisruptive manner, if required.</i>
Ability to establish and maintain strategic relationships	<i>To be successful, IMEXHS must continue to maintain existing strategic relationships and establish additional strategic relationships with leaders in a number of healthcare and health information industry segments. There is no guarantee that IMEXHS will be able to maintain or establish these relationships.</i>
Reliance on third party providers	<i>IMEXHS's products are built to work with various computer operating systems, internet platforms, computing networks and hardware devices. Any changes to external platforms, networks, systems, devices or hardware may give preference to competing products or adversely impact the functionality of IMEXH's products, which may have a detrimental impact on IMEXH's financial performance.</i>
Sales cycles	<i>Variations in timing of sales can cause significant fluctuations in IMEXHS's sales and financial performance. The duration of the sales cycle and implementation schedule for IMEXHS's products and services depend on a number of factors including nature and size of the potential clients and the extent of the commitment being made by the potential client, which are difficult to predict. Sales and marketing efforts with respect to hospitals, health organisations and other potential clients will generally a involve lengthy sales cycle due to these organisations' size and complex decision-making processes.</i>

Key Risks

Risk	Description
Ability to manage growth effectively	<i>IMEXHS will need to continue to expand its operations if it successfully achieves market acceptance of its products and services in new markets. IMEXHS's existing systems, procedures and resources may not be adequate to support such expansion. IMEXHS may experience difficulties in managing any future growth, or may not be able to expand and upgrade its systems and infrastructure to accommodate such growth.</i>
Hosting provider, data loss, theft or corruption	<i>IMEXHS stores data in its own systems and networks and with a variety of third party service providers and hosting facilities located in the cloud. These facilities may be vulnerable to damage or outages, which if prolonged, may have a material adverse impact on IMEXHS's products, business operations and reputation. Further, exploitation or hacking of any of these systems or networks could lead to corruption, theft or loss of data which could have a material adverse effect on the IMEXHS's business, financial condition, and results. Although IMEXHS maintains comprehensive measures to prevent, detect, address and mitigate cybersecurity threats, a cybersecurity incident could potentially result in the misappropriation, destruction, of critical data or proprietary information. The potential consequences of a material cybersecurity incident include reputational damage, compromised employee, customer, or third-party information, litigation with third parties, regulatory actions, and increased cybersecurity protection and remediation costs.</i>
Foreign exchange risks	<i>IMEXHS's operations are based in Colombia and the majority of IMEXHS's current revenue is in Colombian Pesos and other Latin American currencies while its financial results are reported in Australian dollars. As a result, IMEXHS's financial results may be affected by any currency fluctuations and volatility. In addition, the proceeds of the Placement and Entitlement Offer will be received primarily in Australian dollars while the majority of the Company's expenditure is in Colombian Pesos, so the Company may be exposed to exchange rate fluctuations on the conversion.</i>
Regulatory risks	<i>As with any technology offering, IMEXHS's products and services may be exposed to the regulatory environment of different jurisdictions, which may be complex and ever-changing. IMEXHS may also be subject to a number of domestic and international government regulations regarding the use of software in medical diagnostics and the use and storage of medical data. There is a risk that IMEXHS's products and services will not always comply with all applicable laws and regulations.</i>

Key Risks

Risk	Description
Doing business outside of Australia	<i>IMEXHS currently has employees in Colombia and Mexico and distributors engaged in Mexico and other Latin American countries. IMEXHS may wish to engage further employees and distributors outside of Australia as it grows its existing business and expands to new markets. This exposes IMEXHS to a range of multi-jurisdictional risks including modern slavery labour practices, environmental matters, difficulty in enforcing contracts, changes to the legal and regulatory environment and other issues.</i>
Impact of COVID-19	<i>IMEXHS's business and operations may be exposed to the effects of COVID-19. The consequences of the COVID-19 pandemic continue to be felt around the world. No current significant impact on the business being observed.</i>
Economic conditions	<i>General economic conditions, introduction of tax reform, movements in interest and inflation rates and currency exchange rates generally may have an adverse effect on IMEXHS's activities, as well as on its ability to fund those activities. Deterioration in general economic conditions, including factors that impact negatively on IMEXHS's customers ability to finance may adversely affect IMEXHS's profitability.</i>
Market conditions and price volatility	<i>Market conditions may affect the value of IMEXHS's shares regardless of its operating performance. Share market conditions are affected by many factors such as, general economic outlook, interest rates, inflation rates, exchange rates, changes in investor sentiment toward particular market sectors. There can be no guarantee that the price of IMEXHS shares will increase or remain at the Offer Price. There may also be relatively few potential buyers or sellers at any given time and this may increase the volatility of the market price of IMEXHS shares.</i>
Dilution	<i>Current shareholders who do not participate pro rata in the Entitlement Offer will have their percentage holding in IMEXHS diluted. Shareholders may also have their investment diluted by future capital raisings or issues of new equity securities by IMEXHS. IMEXHS may issue new equity securities in the future for various reasons including to finance acquisitions, pay down debt and/or fund expansion which may dilute the value of a shareholder's interest in IMEXHS.</i>

Summary of Underwriting Agreement

IMEXHS Limited ACN 096 687 839 (**IMEXHS**) has entered into an underwriting agreement with Morgans Corporate Limited ACN 010 539 607 (**Lead Manager**), (**Agreement**) under which the Lead Manager has agreed to manage and underwrite the placement to institutional and sophisticated investors (**Placement**) and pro rata non-renounceable entitlement offer (**Entitlement Offer**) of fully paid ordinary shares in the capital of IMEXHS (together, the **Offer**).

The Agreement contains customary representations and warranties and indemnities in favour of the Lead Manager for an agreement of this nature.

IMEXHS will pay the Lead Manager a management and underwriting fee equal to 6% of the underwritten amount of \$4 million under the Offer less the aggregate \$1.5 million committed by the Directors and 4% on the amount committed by the Directors. The Company must also pay to the Lead Manager its reasonable expenses including legal costs and out-of-pocket expenses incurred by the Underwriter in relation to the Placement.

The Lead Manager's obligations under the Agreement, including to manage and underwrite the Offer are conditional on certain matters, including IMEXHS delivering certain certificates, reports, sign-offs and opinions. The Lead Manager's obligations to underwrite tranche two of the Placement (the Conditional Placement) are also subject to shareholder approval being obtained by IMEXHS to permit the relevant directors / their associates to be issued shares under the Conditional Placement. Further, if certain events occur, some of which are beyond the control of IMEXHS, the Lead Manager may terminate the Agreement. Termination of the Agreement may have a materially adverse impact on the total amount of proceeds that could be raised under the Offer. Some of the termination events are detailed below.

The Lead Manager may terminate its obligations under the Agreement if any of the following events (amongst others) occur, provided that the event satisfies a materiality qualification or has given, or could reasonably be expected to give rise to, the Lead Manager being involved in a contravention of an applicable law or

Termination Events	
Index fall	If at any time, the ASX/S&P All Ordinaries Index of ASX closes 10% or more below its level at the close of trading on the business day before the date of the Agreement and remains at that level for three consecutive business days or has fallen by such level on the business day immediately prior to the settlement date of the Entitlement Offer, being the business day prior to the date the shares are allotted under the Entitlement Offer.
Disruption in financial markets or trading	If securities on the ASX, the London Stock Exchange, the New York Stock Exchange, the Hong Kong Stock Exchange or New Zealand's Exchange are suspended or limited in a material respect for more than one day on which that exchange is open for trading or there is any adverse change or material disruption to the existing financial markets, political or economic conditions of Australia, Hong Kong, New Zealand, the United Kingdom or the United States of America.
Material adverse change	A material adverse change occurs in the business, assets, liabilities, financial position or performance, profits, losses, operations, results or prospects of the IMEXHS or the IMEXHS group.

Summary of Underwriting Agreement


Defective documentation	<i>A statement in the Offer documentation (whether by omission or otherwise) is or becomes false, misleading or deceptive in a material particular or is likely to mislead or deceive, or the documentation in respect of the Offer fails to comply with all applicable laws.</i>
Hostilities	<i>If hostilities not presently existing commence, or a major escalation in existing hostilities occurs, in any one or more of the United States of America, Australia, New Zealand, the United Kingdom, Colombia, China or Hong Kong, any of these countries declare a national emergency (other than as a result of the COVID-19 pandemic) or war or a major terrorist act is perpetrated anywhere in the world.</i>
Insolvency	<i>IMEXHS or any group member of IMEXHS becomes insolvent or there is an act or omission which will or is likely to result in IMEXHS or any group member of IMEXHS becoming insolvent.</i>
ASX action	<i>If unconditional approval by ASX for official quotation of any shares to be issued under the Offer is refused, or is not granted by the time indicated in the timetable set out in the Agreement, or ASX makes an official statement to any person or indicates to IMEXHS or the Lead Manager that official quotation of any shares to be issued under the Offer will not be granted, if existing shares in IMEXHS are suspended from quotation or cease to be quoted on the ASX, or IMEXHS is removed from the official list of the ASX.</i>
Due diligence materials misleading	<i>The information provided by or on behalf of the Company in respect of the due diligence process undertaken in connection with the Offer is misleading or deceptive, or any other due diligence results provided by or on behalf of the Company to the Lead Manager was at the time completed false or misleading or deceptive.</i>
Indictable offence	<i>A director of the Company is charged with an indictable offence relating to any financial or corporate matter or is disqualified from managing a corporation under the Corporations Act 2001 (Cth).</i>
Breach of warranty	<i>A representation or warranty made or given by the Company under the Agreement proves to be, or has been, or becomes, untrue or incorrect.</i>
ASIC action	<i>ASIC issues or threatens to issue proceedings or prosecute IMEXHS or commences any hearing or investigation in relation to the Entitlement Offer or the Offer documents which becomes public or is not withdrawn within 2 business days after it is commenced or by the settlement date of the Entitlement Offer (if earlier).</i>
Regulatory action	<i>There is an application to a government agency for an order, declaration or other remedy, or a government agency commences any investigation or hearing or announces its intention to do so, in connection with the Entitlement Offer or any agreement entered into in respect of the Entitlement Offer.</i>
Change in directors or management	<i>There is a change to the board of directors or senior management of IMEXHS, or such a change is announced.</i>



Appendices



2025+ Endgame



5-year Strategy Framework

2026+ Harvesting

10% Resource Allocation

2024 | 2025 Growing (Product Offering)

20% Resource Allocation

2022 | 2023 Seeding (Scale-Up)

70% Resource Allocation

Cost saving initiatives announced will not have significant impact on achieving milestones

IMEXHS Cloud

- Single Unified Medical Imaging Software Platform
- SaaS/PaaS architecture
- Other ologies

Digital pathology

Single Software Platform (Base + Extensions)

Medical Services (Radiology + Pathology)

AI

- Dedicated team
- Data Lake
- Integrated engine
- Algorithms development

AI

Growth Strategy for three business segments

1. IMEXHS Cloud SME
2. IMEXHS Cloud Enterprise
3. Radiology Services

Based on four areas:

1. Product – **Unified Medical Imaging Platform**
2. Sales – **Dynamic Proactive Sales Team**
3. Customer segmentation
4. Geographic expansion

Radiology Services

- International outsourcing & teleradiology services powered by AI

Medical Imaging Services Platform

Partner of choice for:

- Medical Imaging Apps
- Powered by AI
- Healthcare Services (Radiology, Pathology & others)

Disclaimer

Foreign selling restrictions

New Zealand

Shares are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.

This document has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013. This document is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

Colombia

Shares have not been, and will not be, registered with the Colombian National Registry of Securities and Issuers (Registro Nacional de Valores y Emisores) maintained by the Superintendence of Finance of Colombia (Superintendencia Financiera de Colombia, or the "SFC") and will not be listed on the Colombian Stock Exchange (Bolsa de Valores de Colombia). Accordingly, Shares may not be offered or sold in Colombia except under circumstances that do not constitute a public offering of securities under applicable Colombian securities laws. This document may be distributed solely on a private and confidential basis by the Company to existing shareholders of the Company.

imexHS

Investor Presentation

3 August 2022